Corcept Therapeutics CORT Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's total revenue?
- Corcept Therapeutics (CORT) reported total revenue of $164.9M in Q1 2026.
- How has Corcept Therapeutics's total revenue changed year-over-year?
- Corcept Therapeutics's total revenue increased by 4.9% year-over-year, from $157.21M to $164.9M.
- What is the long-term trend for Corcept Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Corcept Therapeutics's total revenue has grown at a 20.1% compound annual growth rate (CAGR), from $365.98M to $761.41M.
- What does total revenue mean?
- The total amount of money a company brings in from sales before any expenses are subtracted.
- How do you interpret total revenue?
- An increase indicates growing market share or successful product adoption, while a decrease may signal market saturation or competitive pressure.
- How does total revenue compare across companies?
- Standard across all industries; peers in biopharma typically show steady growth correlated with drug commercialization cycles.